RACE-2L: Real-World Assessment of Clinical Practice and Outcomes in Non-squamous NSCLC After Failure of Platinum-based Chemotherapy in Brazil
NCT Number: NCT06491862
Acronym: RACE-2L
Status: RECRUITING
Study Type: OBSERVATIONAL
Conditions: Non-squamous Non-Small Cell Lung Cancer
Sponsor: AstraZeneca
Sex: ALL
Age: ADULT, OLDER_ADULT
Enrollment: 250
Study Design: Observational Model: |Time Perspective: p
Start Date: 2024-07-25
Completion Date: 2025-03-31
Locations: Research Site, Natal, Rio Grande Do Norte, 59062-000, Brazil|Research Site, Sao Paulo, 01308-050, Brazil|Research Site, Sao Paulo, 01323-020, Brazil|Research Site, Sao Paulo, 01333-010, Brazil|Research Site, Sao Paulo, 05652-900, Brazil

Summary:
The study will be implemented as a retrospective, noninterventional medical record review of patients from routine practice settings who have been diagnosed with a/m non-squamous NSCLC with or without AGA and received at least 1 line of systemic treatment after failing PTC between January 2017 and December 2022.

Primary Outcome Measures: Describe the patient population and treatment patterns, Description of patient population and treatment patterns: tumor histology, mutation and PD-L1 status, disease stage at diagnosis, between January 1st 2017 and December 31th 2022|Describe the patient population and treatment patterns, Description of patient population and treatment patterns: disease stage at diagnosis, between January 1st 2017 and December 21th 2022|Describe the patient population and treatment patterns, Description of patient population and treatment patterns: smoking status, between January 1st 2017 and December 21th 2022|Describe the patient population and treatment patterns, Description of patient population and treatment patterns: age, between January 1st 2017 and December 31th 2022|Describe the patient population and treatment patterns, Description of patient population and treatment patterns: gender, between January 1st 2017 and December 31th 2022|Describe the patient population and treatment patterns, Description of patient population and treatment patterns: presence of brain metastasis at diagnosis, between January 1st 2017 and December 31th 2022|Describe the patient population and treatment patterns, Description of patient population and treatment patterns: comorbidities (based on Charlson Comorbity Index), between January 1st 2017 and December 31th 2022|Describe the patient population and treatment patterns, Description of patient population and treatment patterns: treatments used prior to the index date, their start and end time and response, between January 1st 2017 and December 31th 2022|Describe the patient population and treatment patterns, Description of patient population and treatment patterns: treatments used after the index date, between January 1st 2017 and December 31th 2022|Describe the patient population and treatment patterns, Description of patient population and treatment patterns: weight, between January 1st 2017 and December 31th 2022|Describe the patient population and treatment patterns, Description of patient population and treatment patterns: height, between January 1st 2017 and December 31th 2022|Describe the patient population and treatment patterns, Description of patient population and treatment patterns: weight change between first treatment for metastatic disease and treatment index, between January 1st 2017 and December 31th 2022|Describe the patient population and treatment patterns, Description of patient population and treatment patterns: starting dose of the index treatment, between January 1st 2017 and December 31th 2022|Describe of the population and treatment patterns, Description of patient population and treatment patterns: duration of therapy, between January 1st 2017 and December 31th 2022|Describe the patient population and treatment patterns, Description of patient population and treatment patterns: reasons for discontinuation, between January 1st 2017 and December 31th 2022